- Home
- XXII vs APRE Comparison
XXII vs APRE Comparison
Compare XXII & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XXII | APRE |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | XXII | APRE |
|---|---|---|
| Price | $0.85 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 160.0K | 70.4K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,346,000.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $0.78 | $0.90 |
| 52 Week High | $287.27 | $5.00 |
Technical Indicators
Market Signals| Indicator | XXII | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 43.65 |
| Support Level | $0.90 | $0.91 |
| Resistance Level | $0.97 | $1.14 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 9.62 | 39.31 |
Price Performance
Historical ComparisonAbout XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.